- ￥570 - 5880
- MedChemExpress(MCE)
- 美国
- HY-101295
- 2025年12月05日
企业认证
相关产品推荐更多 >
万千商家帮你免费找货
0 人在求购买到急需产品
- 详细信息
- 文献和实验
- 技术资料
- 保存条件：
Powder: -20°C, 3 years; 4°C, 2 years.In solvent: -80°C, 6 months; -20°C, 1 month.
- 库存：
货期：1-2天
- 供应商：
MedChemExpress LLC
- CAS号：
1835283-94-7
- 规格：
10 mM * 1 mL/1 mg/5 mg/10 mg/25 mg/50 mg
| 规格： | 10 mM * 1 mL | 产品价格： | ￥1989.0 |
|---|---|---|---|
| 规格： | 1 mg | 产品价格： | ￥570.0 |
| 规格： | 5 mg | 产品价格： | ￥1260.0 |
| 规格： | 10 mg | 产品价格： | ￥1960.0 |
| 规格： | 25 mg | 产品价格： | ￥3920.0 |
| 规格： | 50 mg | 产品价格： | ￥5880.0 |
MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务。
Pan-RAS-IN-1
CAS No. : 1835283-94-7
MCE 国际站：Pan-RAS-IN-1
产品活性：Pan-RAS-IN-1是一种pan-Ras抑制剂，破坏Ras蛋白及其作用子的相互作用。
研究领域：GPCR/G Protein
作用靶点：Ras
In Vitro: Pan-RAS-IN-1 binds to KRasG12D-GppNHp with an affinity less than 20 μM. Pan-RAS-IN-1 binds to Ras proteins and exhibits lethality in cells partially dependent on expression of Ras proteins. The potency of pan-RAS-IN-1 correlates with the degree of dependency on the mutated isoform over a 5-fold concentration range. At some concentrations, pan-RAS-IN-1 is cytostatic, possibly due to pan-RAS inhibition. Pan-RAS-IN-1 is evaluated in primary T cell acute lymphoblastic leukemia (T-ALL) cells. Selective lethality is observed, with mutant NRAS cells retaining only 20%-40% viability after 5 μM treatment.
In Vivo: Pan-RAS-IN-1 administration results in inhibition of tumor growth over 15 days of treatment. Pan-RAS-IN-1-treated mice exhibits decreased tumor pERK levels compared with vehicle treated mice. A modest increase in cleaved caspase-3 is also observed, showing that in this model, pan-RAS-IN-1 has the capacity to induce caspase activation.
相关产品：Bioactive Compound Library Plus | GPCR/G Protein Compound Library | Kinase Inhibitor Library | Anti-Cancer Compound Library | Ferroptosis Compound Library | Glutamine Metabolism Compound Library | Anti-Pancreatic Cancer Compound Library | Anti-Blood Cancer Compound Library | Angiogenesis-Related Compound Library | Anti-Liver Cancer Compound Library | Anti-Colorectal Cancer Compound Library | Heterocyclic Compound Library | Membrane Protein-targeted Compound Library | Membrane Receptor-targeted Compound Library | Sotorasib | MRTX1133 | Adagrasib | BI-2852 | BI-3406 | Ketoconazole | NSC 23766 trihydrochloride | BI-2865 | ML141 | BAY-293 | CID-1067700 | Rhosin hydrochloride | Lonafarnib | EHT 1864 | GGTI298 Trifluoroacetate | MBQ-167 | MRTX0902 | Opnurasib | Divarasib | ARS-1620 | CCG-1423 | CASIN | Salirasib | EHop-016 | RMC-6291 | ML-098 | MRTX-1257 | FTI-277 hydrochloride
热门产品线：重组蛋白 | 化合物库 | 天然产物 | 荧光染料 | PROTAC | 同位素标记物
Trending products：Recombinant Proteins | Bioactive Screening Libraries | Natural Products | Dye Reagents | PROTAC | Isotope-Labeled Compounds
风险提示：丁香通仅作为第三方平台，为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全，合理判断，谨慎选购商品，商家和用户对交易行为负责。对于医疗器械类产品，请先查证核实企业经营资质和医疗器械产品注册证情况。
文献和实验PNAS：RAS 抑制剂又添一员，新型蛋白模拟物或为癌症治疗
-Sos 复合体结构为合理设计稳定的 Ras 抑制剂提供了依据。来自纽约大学的 Paramjit S. Arora 团队在 PNAS 在线发表了题为 A Sos proteomimetic as a pan-Ras inhibitor [1] 的文章。该研究开发了一种结构稳定的 Sos 蛋白模拟物，可与野生型和致癌型 Ras 非共价结合，并调节下游激酶信号。该模拟物能够抵抗蛋白水解并进入癌细胞，对巨胞饮作用上调的癌细胞具有选择性毒性，包括那些具有致癌 Ras 突变的细胞，为开发 Ras 突变型癌症非
Panhandle PCR Approaches to Cloning MLL Genomic Breakpoint Junctions and Fusion Transcript Sequences
in leukemias with del(11)(q23), a normal karyotype, or trisomy 11, the latter two of which sometimes are associated with partial tandem duplications of MLL itself (Proc Natl Acad Sci USA 97:2814–2819, 2000; Proc Natl Acad Sci USA 94:3899–3902, 1997
CGAAACG-3′ product size 80bp 非甲基化引物 上游为5′- TTTGTG TTTTGATGTTTGTAGGTTTTTGT-3′ 下游为5′- AACTCCA CACTC TTCCAAAAACAAAACA-3′ product size 94bp 参考：Tae Jun Park, Sang-Uk Han, Yong-Kwan Cho,et al. Methylation of O6- Methylguanine-DNA Methyltransferase Gene
技术资料暂无技术资料 索取技术资料
